AGS-16C3F

an antibody-drug conjugate (ADC) against ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) containing the mcMMAF linker-payload currently in development for treatment of metastatic renal cell carcinoma.

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Doñate, Fernando: 4 articles (01/2019 - 01/2017)
2.	Morrison, Karen: 3 articles (01/2018 - 01/2017)
3.	Choueiri, Toni K: 2 articles (01/2021 - 01/2018)
4.	Thompson, John A: 2 articles (01/2021 - 01/2018)
5.	Aviña, Hector: 2 articles (01/2018 - 01/2017)
6.	Gulesserian, Sara: 2 articles (01/2018 - 01/2017)
7.	Karki, Sher: 2 articles (01/2018 - 01/2017)
8.	Ou, Jimmy: 2 articles (01/2018 - 01/2017)
9.	Snyder, Josh: 2 articles (01/2018 - 01/2017)
10.	Stover, David R: 2 articles (01/2018 - 01/2017)

Related Diseases

1.	Renal Cell Carcinoma (Grawitz Tumor) 01/01/2021 - "Here we present findings from a phase II study of AGS-16C3F versus axitinib in metastatic renal cell carcinoma (mRCC). " 01/01/2021 - "The primary endpoint of this phase II study that evaluated the efficacy and safety of the investigational compound, AGS-16C3F, versus axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC) was not met. " 01/01/2021 - "A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma." 01/01/2018 - "AGS-16C3F is an antibody-drug conjugate (ADC) against ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) containing the mcMMAF linker-payload currently in development for treatment of metastatic renal cell carcinoma. " 01/01/2018 - "Purpose: To determine the safety, pharmacokinetics, and recommended phase II dose of an antibody-drug conjugate (ADC) targeting ectonucleotide phosphodiesterases-pyrophosphatase 3 (ENPP3) conjugated to monomethyl auristatin F (MMAF) in subjects with advanced metastatic renal cell carcinoma (mRCC).Patients and Methods: Two phase I studies were conducted sequentially with 2 ADCs considered equivalent, hybridoma-derived AGS-16M8F and Chinese hamster ovary-derived AGS-16C3F. "
2.	Nausea 01/01/2021 - "Median progression-free survival, the primary endpoint, was 2.9 months with AGS-16C3F and 5.7 months with axitinib (HR, 1.676; 95% CI, 1.107-2.537; p = .015), per investigator assessment The safety profile for each study drug was as expected, with the most commonly reported adverse events being fatigue (53%) and nausea (47%) in the AGS-16C3F arm and fatigue (57%) and diarrhea (48%) in the axitinib arm. " 01/01/2021 - "In the safety population (n = 131), the most commonly reported adverse events were fatigue (53%) and nausea (47%) in the AGS-16C3F arm and fatigue (57%) and diarrhea (48%) in the axitinib arm. "
3.	Fatigue 01/01/2021 - "Median progression-free survival, the primary endpoint, was 2.9 months with AGS-16C3F and 5.7 months with axitinib (HR, 1.676; 95% CI, 1.107-2.537; p = .015), per investigator assessment The safety profile for each study drug was as expected, with the most commonly reported adverse events being fatigue (53%) and nausea (47%) in the AGS-16C3F arm and fatigue (57%) and diarrhea (48%) in the axitinib arm. " 01/01/2021 - "In the safety population (n = 131), the most commonly reported adverse events were fatigue (53%) and nausea (47%) in the AGS-16C3F arm and fatigue (57%) and diarrhea (48%) in the axitinib arm. "
4.	Diarrhea 01/01/2021 - "The incidence of diarrhea was lower in the AGS-16C3F arm than in the axitinib arm (17% vs. 48%), and ocular toxicities were more frequent in the AGS-16C3F arm than in the axitinib arm (44% vs. 26%). " 01/01/2021 - "Median progression-free survival, the primary endpoint, was 2.9 months with AGS-16C3F and 5.7 months with axitinib (HR, 1.676; 95% CI, 1.107-2.537; p = .015), per investigator assessment The safety profile for each study drug was as expected, with the most commonly reported adverse events being fatigue (53%) and nausea (47%) in the AGS-16C3F arm and fatigue (57%) and diarrhea (48%) in the axitinib arm. " 01/01/2021 - "In the safety population (n = 131), the most commonly reported adverse events were fatigue (53%) and nausea (47%) in the AGS-16C3F arm and fatigue (57%) and diarrhea (48%) in the axitinib arm. "
5.	Disease Progression 01/01/2021 - "Patients with mRCC of any histology and disease progression during or after their last treatment regimen were randomized 1:1 to intravenous AGS-16C3F 1.8 mg/kg every 3 weeks or oral axitinib 5 mg twice daily (starting dose). "

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Pyrophosphatases
3.	Phosphoric Diester Hydrolases (Phosphodiesterases)
4.	Axitinib (AG 013736)
5.	monomethylauristatin F
6.	Ado-Trastuzumab Emtansine